SCHEMBL137418

SCHEMBL137418

COC(=O)c1cc(Br)nc2c1[nH]c1cc(C=O)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.41
GSK3B P49841 1/20 0.39
MPL P40238 1/20 0.38
KIF11 P52732 2/20 0.37
ALDH1A1 P00352 3/20 0.37
DYRK1A Q13627 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
NR4A2 P43354 3/20 0.36
PIM1 P11309 2/20 0.35
PIM3 Q86V86 2/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
THRB P10828 1/20 0.35
MIF P14174 1/20 0.35
APEX1 P27695 1/20 0.35
RECQL P46063 1/20 0.35
DUSP3 P51452 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143722 0.91 NR4A2 (0.38) JAK2MPLKIF11ALDH1A1L3MBTL1
SCHEMBL145786 0.85 JAK2 (0.43) JAK2MPLKIF11ALDH1A1DYRK1A
SCHEMBL138263 0.84 JAK2 (0.57) JAK2GSK3BALDH1A1DYRK1ANR4A2
SCHEMBL145169 0.84 NR4A2 (0.51) JAK2MPLNR4A2KDM4EMEN1
SCHEMBL141121 0.84 JAK2 (0.42) JAK2MPLKIF11ALDH1A1DYRK1A
SCHEMBL145348 0.80 PRMT5 (0.42) JAK2ALDH1A1MAPTMEN1KMT2A
SCHEMBL142806 0.79 DYRK1A (0.44) JAK2GSK3BMPLKIF11ALDH1A1
SCHEMBL141085 0.79 JAK2 (0.53) JAK2NR4A2
SCHEMBL141886 0.77 JAK2 (0.55) JAK2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL142902 0.77 JAK2 (0.55) JAK2MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885GSK3B 151/4885MPL 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.